631 related articles for article (PubMed ID: 16722814)
1. Albumin-bound paclitaxel: a next-generation taxane.
Gradishar WJ
Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
[TBL] [Abstract][Full Text] [Related]
2. Albumin-bound Paclitaxel: in metastatic breast cancer.
Robinson DM; Keating GM
Drugs; 2006; 66(7):941-8. PubMed ID: 16740010
[TBL] [Abstract][Full Text] [Related]
3. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.
Chen N; Brachmann C; Liu X; Pierce DW; Dey J; Kerwin WS; Li Y; Zhou S; Hou S; Carleton M; Klinghoffer RA; Palmisano M; Chopra R
Cancer Chemother Pharmacol; 2015 Oct; 76(4):699-712. PubMed ID: 26231955
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Petrelli F; Borgonovo K; Barni S
Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
[TBL] [Abstract][Full Text] [Related]
5. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
[TBL] [Abstract][Full Text] [Related]
6. nab-Paclitaxel mechanisms of action and delivery.
Yardley DA
J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
[TBL] [Abstract][Full Text] [Related]
7. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
Guarneri V; Dieci MV; Conte P
Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
[TBL] [Abstract][Full Text] [Related]
8. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
9. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
12. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
Jain MM; Gupte SU; Patil SG; Pathak AB; Deshmukh CD; Bhatt N; Haritha C; Govind Babu K; Bondarde SA; Digumarti R; Bajpai J; Kumar R; Bakshi AV; Bhattacharya GS; Patil P; Subramanian S; Vaid AK; Desai CJ; Khopade A; Chimote G; Bapsy PP; Bhowmik S
Breast Cancer Res Treat; 2016 Feb; 156(1):125-34. PubMed ID: 26941199
[TBL] [Abstract][Full Text] [Related]
14. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Ando M; Yonemori K; Katsumata N; Shimizu C; Hirata T; Yamamoto H; Hashimoto K; Yunokawa M; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2012 Feb; 69(2):457-65. PubMed ID: 21853310
[TBL] [Abstract][Full Text] [Related]
16. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
[TBL] [Abstract][Full Text] [Related]
17. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients.
Borgå O; Lilienberg E; Bjermo H; Hansson F; Heldring N; Dediu R
Adv Ther; 2019 Oct; 36(10):2825-2837. PubMed ID: 31432461
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
20. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
Lipp HP
Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]